key: cord-0939263-atangn4o authors: Moreno‐Perez, Oscar; Merino, Esperanza; Alfayate, Rocio; Torregrosa, Maria Eugenia; Andres, Mariano; Leon‐Ramirez, Jose‐Manuel; Boix, Vicente; Gil, Joan; Pico, Antonio title: Male pituitary–gonadal axis dysfunction in post‐acute COVID‐19 syndrome—Prevalence and associated factors: A Mediterranean case series date: 2021-07-23 journal: Clin Endocrinol (Oxf) DOI: 10.1111/cen.14537 sha: 756726a6d434e5c66a11019c7cde08745536fd4f doc_id: 939263 cord_uid: atangn4o OBJECTIVE: Severe acute respiratory syndrome coronavirus 2 through angiotensin‐converting enzyme 2 receptor can harm testes function. The objectives were to analyse the prevalence of low serum testosterone (LT) and impaired fertility potential (Leydig and Sertoli cells dysfunction, respectively) in coronavirus disease 2019 (COVID‐19) male survivors and to evaluate acute infection‐related associated factors. Also, we explore its association with post‐acute COVID‐19 syndrome (PCS) and quality of life (QOL). MATERIALS AND METHODS: Male adults recovered from polymerase chain reaction‐confirmed COVID‐19 were offered a structured evaluation 8–12 weeks after recovery. The main outcome measure(s) were as follows: LT, defined as total testosterone (TT) < 2 ng/ml or if TT levels 2–4 ng/ml as calculated free testosterone < 6.36 ng/dl; Sertoli cell dysfunction was defined as inhibin‐B < 89 pg/ml. Secondary outcome‐associated factors were analysed by multiple logistic regression (odds ratio; 95% confidence interval [CI]). QOL was evaluated by SF‐36 v.2. RESULTS: One hundred and forty‐three patients were evaluated at a median (interquartile range) of 77 days (72–83) after disease onset; 72% of them recovered from severe pneumonia. LT was detected in 41 patients (28.7%; 95% CI: 21.8–36.5). Low levels of inhibin‐B were detected in 25 patients (18.1%; 95% CI: 12.5–25.3). After multivariate adjustment, obesity and hypokalaemia were associated with LT, whereas age more than 65 was an independent predictor of Sertoli cell dysfunction. LT or Sertoli cell dysfunction was not associated with PCS. Patients with LT had a lower score in four domains of QOL. CONCLUSIONS: Prevalence of male LT and impaired fertility potential in COVID‐19 survivors is high in the medium term. Traditional risk factors and severity markers for COVID‐19 could be predictive. The battle against coronavirus disease 2019 (COVID- 19) seems not limited to screening and management of the acute disease. COVID-19 also has widespread effects throughout the body with lesser known clinical manifestations, and the medium-and long-term health consequences experienced by survivors of COVID-19, if any, are currently unknown. 1 Knowledge about the impact of this virus on the endocrine system is growing. 2 Severe acute respiratory syndrome coronavirus (SARS-CoV) was able to cause orchitis and germ cell destruction in human testes. 3 The messenger RNA for angiotensin-converting enzyme 2 (ACE2) (genomic coordinates (GRCh38): X: 15, 518, 602, 157) , the receptor for COVID-19, is highly expressed in human testes, primarily in spermatogonia, Leydig cells and Sertoli cells. 4, 5 Hence, ACE2 plays vital roles in spermatogenesis-reproductive function and the regulation of steroidogenesis. Therefore, there is potential for SARS-CoV-2 to invade the testes via ACE2 and interfere with testosterone release and Sertoli cells function. A pattern of elevated luteinising hormone (LH) without testosterone changes has been reported in hospitalised patients with confirmed COVID-19. It suggests an early gonadal failure and speaks against a direct COVID-19 effect at hypothalamus or pituitary gland. 6 This testicular defect could be caused by direct testicular damage by the virus or by an indirect inflammatory/immune response in the testicles. 7 We lack data about the pituitary-gonadal axis of male patients recovered from COVID-19 acute infection in the medium and long term, as well as the possible effects of disease severity and the treatments used for the disease. This study aims to analyse the medium-term Leydig and Sertoli cells dysfunction through a hormonal evaluation in survivor male patients and to evaluate the acute infection phaseassociated factors. In addition, we explore its association with post-acute COVID-19 syndrome (PCS) and quality of life (QOL). Surviving patients of COVID-19 were offered an assessment by COVID-19 medical team 8-12 weeks after ambulatory COVID-19 recovery or discharge from hospital. A structured evaluation was performed in the same visit: clinical examination, fasting (8) (9) (10) blood test, Chest-X-ray, pulmonary function test and quality-of-life assessment by EuroQol Visual Analogue Scale. 9 Of 237 male patients evaluated in the emergency department, 37 (15.6%) died, and 28 were not included in the present study: 18 with severe comorbidity, 5 with follow-up in other health areas and 5 being monitored by other physicians. Also, 3 patients refused to participate, 8 patients did not attend the face-to-face assessment (although a telephone interview was conducted) and 18 patients were lost to follow-up. Finally, 143 (71.5% of the survivors) were included in the study. Patients without assessment, excluded from the analysis, did not differ in severity from the study population. No patient was on testosterone as hormone replacement therapy before admission or during follow-up. The clinical features, comorbidity (Charlson index 10 ), complementary examinations, established therapies and evolution during the acute phase of the infection by SARS-CoV-2 and after recovery from the acute phase were extracted from the digital medical record. The systematic approach in patients who had recovered from COVID-19 include the evaluation of PCS (defined as the persistence of at least one clinically relevant symptom or abnormalities in spirometry or chest radiology) 11 and the QoL by SF-36 v.2 Health Survey. 12 Primary -Low serum testosterone was defined as total testosterone (TT) < 2 ng/ml (6.9 nmol/L) or in those with borderline TT levels 2-4 ng/ ml (6.9-13.9 nmol/l) as a calculated free testosterone (CFT) < 6.36 ng/dl (<0.22 nmol/L), according to the normal range for healthy young males in our laboratory. 13, 14 CFT was calculated by determining TT, sex hormone binding globulin (SHBG) and albumin from the equation described by Vermeulen et al. 15 -Sertoli cell dysfunction, spermatogenesis disruption, was defined as inhibin-B < 89 pg/ml (89 ng/L), cutoff derived from 2.5 percentile T A B L E 1 General characteristics of the global study population and patients with gonadal dysfunction inhibin-B in a cohort of young men unbiased with regard to fertility. 16 Inhibin-B/follicle-stimulating hormone (FSH) ratio was calculated. -The pituitary-gonadal axis was evaluated determining the FSH and LH. Secondary dysfunction was defined as low or inappropriately normal gonadotropin levels, 14 LH (for hypogonadism) or FSH concentrations (for Sertoli cell dysfunction). Note: Data shown as %, median (IQR), unless specified otherwise. In bold, statistically significant differences. Mann-Whitney's U and χ 2 tests were used for group comparisons: p1 low serum testosterone versus no low serum testosterone, p2 impaired fertility potential vs no impaired fertility potential. Abbreviations: ARA2/ACEI, angiotensin II receptor antagonists/angiotensin-converting enzyme inhibitors; BMI, body mass index; BP, blood pressure; COVID, coronavirus disease; CURB65, severity score for community-acquired pneumonia 36 ; eGFR, estimated glomerular filtration rate; ICU, intensive care unit; IMV, invasive mechanical ventilation requirement; PaO 2 :FiO 2 , ratio between partial pressure of oxygen in arterial blood (PaO 2 ) and FiO 2 ; QoL, quality of life; TCZ, tocilizumab. a Defined as total testosterone (TT) < 2 ng/ml (6.9 nmol/l) or in those with borderline TT levels 2-4 ng/ml (6.9-13.9 nmol/l) as calculated free testosterone (CFT) <6.36 ng/dl (<0.22 nmol/L), lower than the normal range for healthy young males in our laboratory. 13 Written informed consent was obtained from all the participants, with approval by the institutional review board (EXP. 200145). To the best of our knowledge, this is the first study that has eval- Evidence of gonadal involvement in COVID-19 is scarce and heterogeneous. In the acute phase of the infection, Ma et al., 6 in nonsevere ill hospitalised patients (n = 81), found a higher LH and low TT:LH ratio, without changes in TT versus age-matched healthy men; only C-reactive F I G U R E 1 Scatter plot showing the relationship between serum total testosterone (TT) and luteinising hormone. Low serum testosterone was defined as TT < 2 ng/ml (6.9 nmol/L) or in those with borderline TT levels 2-4 ng/ml (6.9-3.9 nmol/L) as a calculated free testosterone (CFT) < 6.36 ng/dl (<0.22 nmol/L), according to the normal range for healthy young males in our laboratory. 11, 12 Those patients with borderline TT levels 2-4 ng/ml (6.9-13.9 nmol/L) and a CFT < 6. Variables were included as covariates if they showed significant associations in simple models. The 95% confidence intervals (CIs) of the odds ratios have been adjusted for multiple testing. In bold, independent predictors associated with the outcomes. For the purpose of logistic regression, variables were categorised regarding their 75 percentiles within this subpopulation, to show the impact of severe extreme values in the outcomes. For the following variables, standard categorisations were followed: age ≥65 years, estimated glomerular filtration rate (eGFR) < 60 ml/min/m 2 , respectively. Low serum testosterone was included in the impaired fertility potential model, given its strong association at the time of assessment phase, support a greater impairment of gonadal function in COVID-19 infection than in other infectious processes and support a hypothalamic-pituitary origin of the dysfunction of the Leydig cells in the medium term, according to our findings. Post-mortem examinations of testicular tissue from 12 COVID-19 patients showed significantly reduced Leydig cells, as well as oedema and inflammation in the interstitium. 21 Whether SARS-CoV-2 virus can be found in semen is still debated. 22, 23 The factors found associated with low serum testosterone (obesity, hypokalaemia and higher T-troponin) seem to reflect a greater severity of the past illness. Obesity relationship was expected as it may play a key role and contribute to the apparent age- compared with control males) signifying immune impairment by COVID-19 illness. All of these signs would be, for the authors, due to an autoimmune orchitis. However, the ability of this novel coronavirus to induce an autoimmune orchitis is not proven to date. 29 These recent data reinforce and give plausibility to our findings in pituitary-gonadal axis of COVID-19 recovered patients, whereas Sertoli cell dysfunction seems mediated by primary structural damage in the seminiferous tubules. Sertoli cell function declines with age in general population. 16 The loss of the association between older age and impaired fertility Several viruses may cause orchitis in men. Among them, the mumps virus is well known for its testicular tropism and for inducing inflammation, decreased androgen production and degeneration of the seminiferous epithelium that can lead to sterility. 30 Orchitis develops in 5%-37% of all adult patients infected with mumps. 31 Unilateral involvement is the most common, whereas bilateral involvement occurs in 15%-30% of the patients with orchitis. 32 Bilateral orchitis leads to hypofertility with oligospermia and testicular atrophy in 13% of those patients. 33 Morphological studies of mumps-associated orchitis showed the focused nature of the inflammation with interstitial oedema, 30 mimicking COVID-19 features. 21 While seminiferous epithelium degenerated, Sertoli cells seemed little affected, 30 in contrast to the marked decrease in the Sertoli cells observed in COVID- 19. 21 Concerning the consequences of orchitis on testicular endocrine function, Adamopoulos et al. 34 In conclusion, this study provides the first direct evidence about the medium-term influence of COVID-19 on pituitary-gonadal axis and helps to bridge the existing gap in the field, suggesting that more attention to the global gonadal function among patients recovered from SARS-CoV-2 infection is needed. The low serum testosterone does not appear to be related with sequelae of the disease, but it is associated with a worse QoL. Independently of the limitations of these preliminary results, it should be acknowledged that the testis and pituitary-gonadal axis are a target for SARS-CoV-2 and the possibility for longlasting consequences on the endocrine function exists, even for recovered patients. We should be cautious while drawing conclusions from this medium-term data, whether this state of low serum testosterone and impaired fertility potential is permanent or temporary is a question that remains unanswered. of COVID19-ALC research group are as follows Long-term health consequences of COVID-19 SARS-CoV-2 (COVID-19) and the endocrine system Orchitis: a complication of severe acute respiratory syndrome (SARS) scRNA-seq profiling of human testes reveals the presence of the ACE2 receptor, a target for SARS-CoV-2 infection in spermatogonia, Leydig and sertoli Cells ACE2 receptor expression in testes: implications in coronavirus disease 2019 pathogenesis † Effect of SARS-CoV-2 infection upon male gonadal function: a single center-based study Could COVID-19 have an impact on male fertility? WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research The Spanish version of EuroQol: a description and its applications. European Quality of Life Scale A new method of classifying prognostic comorbidity in longitudinal studies: development and validation Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study The Spanish version of the Short Form 36 Health Survey: a decade of experience and new developments Reference ranges for serum and salivary testosterone in young men of Mediterranean region Testosterone therapy in men with hypogonadism: an Endocrine Society Clinical Practice Guideline A critical evaluation of simple methods for the estimation of free testosterone in serum Testicular function in a birth cohort of young men Identification of late-onset hypogonadism in middle-aged and elderly men A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients SARS-CoV-2 pneumonia affects male reproductive hormone levels: a prospective, cohort study Pathological findings in the testes of COVID-19 patients: clinical implications A review of severe acute respiratory syndrome coronavirus 2 infection in the reproductive system Assessment of SARS-CoV-2 in human semen-a cohort study European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: endorsing organization Effect of increased BMI and obesity on the outcome of COVID-19 adult patients: a systematic review and meta-analysis Hypokalemia as a sensitive biomarker of disease severity and the requirement for invasive mechanical ventilation requirement in COVID-19 pneumonia: a case series of 306 Mediterranean patients Clinical utility of cardiac troponin measurement in COVID-19 infection Impaired spermatogenesis in COVID-19 patients Covid-19 and impairment of spermatogenesis: What if fever was the only cause? Viruses in the mammalian male genital tract and their effects on the reproductive system Serological studies on 40 cases of mumps virus infection Mumps orchitis Mumps orchitis: report of a mini-epidemic Pituitary-testicular interrelationships in mumps orchitis and other viral infections Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19 Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study How to cite this article Male pituitary-gonadal axis dysfunction in post-acute COVID-19 syndrome-prevalence and associated factors: a Mediterranean case series This study was supported by the Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain (Grant Number 2020-379); the information of this article has not been presented in any meeting(s). The authors declare that there are no conflict of interests.